Clinical Trials Logo

Filter by:
NCT ID: NCT05051423 Recruiting - Gastric Cancer Clinical Trials

"Mechanisms and Biomarkers of Response and Resistance to Current Targeted Therapies in Gastric Cancer" (THERRES)

THERRES
Start date: November 1, 2019
Phase:
Study type: Observational [Patient Registry]

Our aim was to assess the tumor vascular perfusion pattern in gastric cancer (GC). We used dynamic contrast harmonic imaging endoscopic ultrasound (CHI-EUS) and then we compared the result with the immunohistochemical expression of CD105 and clinico-pathological parameters.

NCT ID: NCT05037929 Not yet recruiting - Clinical trials for Chronic Obstructive Pulmonary Disease

A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

Start date: September 1, 2021
Phase: Phase 2
Study type: Interventional

This study will evaluate the efficacy, safety, and pharmacokinetics of astegolimab in combination with standard of care chronic obstructive pulmonary disease (COPD) maintenance therapy in patients with COPD who are former or current smokers and have a history of frequent exacerbations.

NCT ID: NCT05025371 Completed - Clinical trials for Pancreas Cancer, Duct Cell Adenocarcinoma

THE ROLE OF SISTEMIC IMMUNO-INFLAMATORY FACTORS IN RESECTABLE PANCREATIC ADENOCARCINOMA

Start date: April 1, 2021
Phase:
Study type: Observational

Pancreatic cancer is a highly aggressive malignancy, its prognosis remaining poor despite the current advances in treatment. Systemic inflammatory reaction has been recently recognized as an important factor in the progression of cancer. The immune-inflammatory response has been measured through different scores or ratios, that combine the values of circulating immune cells, like neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), lymphocyte-to-monocyte ratio (LMR), systemic immune-inflammation index (SII), prognostic nutritional index (PNI). The utility of these scores in different types of cancer has been more and more discussed. In pancreatic cancer, there has been no definite conclusion regarding the role of systemic immune-inflammatory factors; since controversies still exist, a deeper exploration of this subject, through more studies is welcomed. Our study intends to analyze the utility of systemic immune-inflammatory markers in resectable pancreatic cancer. Our study is an observational cohort study, with retrospective data collection; it is a single-center study, that takes place in a hospital with experience in hepato-bilio-pancreatic surgery. We intended to evaluate the role of the circulating immune cells (neutrophils, lymphocytes, monocytes) and different immune-inflammatory scores (NLR, LMR, PLR, SII, PNI) in predicting the overall survival of patients diagnosed with pancreatic ductal adenocarcinoma, that undergo curative surgical treatment. We intended to assess the prognosis power of these factors in both preoperative and postoperative settings, as well as their dynamic after surgery. Through this study, we hope to identify easy-to determine and easy-to-use markers that can be incorporated in clinical practice and that can effectively predict survival in pancreatic cancer patients. Nonetheless, we want to explore the dynamic of the immune-inflammatory markers after curative surgery.

NCT ID: NCT05002569 Not yet recruiting - Melanoma Clinical Trials

A Study to Assess Adjuvant Immunotherapy With Relatlimab and Nivolumab Versus Nivolumab Alone After Complete Resection of Stage III-IV Melanoma

RELATIVITY-098
Start date: September 30, 2021
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess relatlimab and nivolumab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.

NCT ID: NCT04979052 Not yet recruiting - Candidemia Clinical Trials

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

Start date: December 2021
Phase: Phase 2
Study type: Interventional

A randomized open label interventional phase 2 pilot study to evaluate safety and efficacy of recombinant Interferon-Gamma 1b in patients with candidemia.

NCT ID: NCT04973488 Completed - Clinical trials for Acute Respiratory Distress Syndrome

Therapeutic Plasma Exchange Followed by Convalescent Plasma Transfusion in Severe and Critically Ill COVID-19 Patients

Start date: July 25, 2020
Phase: Phase 2/Phase 3
Study type: Interventional

Therapeutic plasma exchange (TPE) has been proposed as a rescue therapy in critically ill COVID-19 patients. The aim of this study is to determine whether combining TPE with convalescent plasma (CVP) transfusion early during the intensive care unit (ICU) stay, improves survival among this heterogeneous population.

NCT ID: NCT04949620 Recruiting - Emotional Problem Clinical Trials

An Integrative Platform for Preventing Children's Emotional Disorders

Start date: May 3, 2021
Phase: N/A
Study type: Interventional

The general objective of the study is to test an online platform for the prevention of emotional disorders in children.

NCT ID: NCT04947579 Recruiting - Clinical trials for Spondylitis, Ankylosing

A Study of CC-99677 in Participants With Active Ankylosing Spondylitis

AS SpA axSpA
Start date: August 25, 2021
Phase: Phase 2
Study type: Interventional

This study is designed to learn about response to CC-99677 treatment by measuring signs and symptoms of Ankylosing Spondylitis (AS), objective measures of disease activity, quality of life assessments, pharmacokinetics, safety, and tolerability over a 12-week double-blind period.

NCT ID: NCT04936763 Recruiting - Clinical trials for Dysmorphic Disorder (BDD)

To Assess The Performance And Tolerance Of Janesse 20 In The Volume Restoration Of Labia Majora

Start date: May 28, 2021
Phase: N/A
Study type: Interventional

The use of hyaluronic acid (HA)-based fillers administered by injection to obtain Labia Majora augmentation is performed by many surgeons and gynaecologists in Europe, US and other countries, but few studies have investigated the effectiveness of this procedure. In this open not comparative study, 36 female subjects above or equal to 18 years old at inclusion, seeking genital rejuvenation, who have congenital or post-menopausal hypotrophy of the vulvar Labia Majora (or a diagnosis of Body Dysmorphic Disorder), who have given her informed consent and meet all the eligibility criteria, will be enrolled. Subjects will come to a total of 4 visits over a period of 2 months. The primary objective of the study is to evaluate the performance of the dermal filler by the Global Aesthetic Improvement Scale (GAIS) at day 60 and the safety during all the study. The secondary objectives are the evaluation of volume restoration of Labia Majora (measured by caliper and Ultrasound) and the subjective evaluation (by Genital Appearance Satisfaction Scale) at different visits.

NCT ID: NCT04928430 Recruiting - COVID-19 Clinical Trials

Efficacy and Safety of XAV-19 for the Treatment of Moderate-to-severe COVID-19

Start date: April 28, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of XAV-19 drug in patients with moderate-to-severe COVID-19.